Bronchodilator actions of xanthine derivatives administered by inhalation in asthma

MJ CUSHLEY, ST HOLGATE

From the University Department of Medicine, Southampton General Hospital, Southampton

ABSTRACT The airway response to the inhalation of four alkyl xanthines was studied in 17 subjects with moderately severe asthma (mean FEV₁ 1.19 litres, 42% predicted). Theophylline (10 mg/ml), glycine theophyllinate (50 mg/ml), theophylline ethylenediamine (aminophylline 50 mg/ml), and diprophylline (125 mg/ml) were administered by nebulisation and the airway response was measured as percentage change from baseline of specific airway conductance (sGaw). All xanthine derivatives had an unpleasant taste and produced coughing at the onset of nebulisation. All four xanthines produced a significant increase in sGaw by comparison with saline placebo, with a maximum mean increase from baseline of 35% for theophylline, 40% for glycine theophyllinate, 60% for aminophylline, and 32% for diprophylline. Inhalation of 200 µg salbutamol from a metered dose inhaler produced an additional increase in sGaw of 149%. Thus alkyl substituted xanthines administered by inhalation to patients with asthma cause significant short lived bronchodilatation, but this effect is small compared with that of a conventional dose of an inhaled β₂ adrenoceptor agonist.

Methylxanthines such as theophylline and aminophylline have been used for the treatment of asthma since 1922¹ and currently many preparations are available for oral, rectal, and parenteral administration. The narrow therapeutic index of these drugs and the wide intersubject variations of metabolism have, however, hindered their use as first line treatment for asthma in Europe. Over the last five years the introduction of serum drug concentration monitoring, together with the availability of oral slow release preparations, has led to the increased use of theophylline and related compounds as adjuncts to other forms of asthma treatment. The accepted serum therapeutic range of 10–20 µg theophylline/ml (55–110 µmol/l) represents a compromise between clinical efficacy and toxicity.² In clinical practice extremes of both toxic and subtherapeutic theophylline concentrations are frequently found, which emphasises the need for drug concentration monitoring if these drugs are to be used effectively.³

An alternative approach is to widen the therapeutic index of methylxanthines by administering them by inhalation, in line with β adrenoceptor agonists, corticosteroids, sodium cromoglycate, and anticholinergic agents.⁴ Administration of drugs by inhalation is preferable to the oral route because it allows high doses to be delivered directly to the airways for a specific pharmacological effect with low systemic concentration and few side effects. A theophylline preparation for inhalation would offer many advantages. Few studies have been carried out with inhaled xanthine derivatives and in these any small improvement in pulmonary function has been outweighed by their unpleasant taste and irritant properties.⁵ ⁶

We have investigated the bronchodilator effects of four alkyl substituted xanthines administered by inhalation to patients with moderately severe asthma. The preparations selected were theophylline, two more soluble theophylline salts, aminophylline and glycine theophyllinate, and an N-7 substituted xanthine derivative, diprophylline, which is currently available for parenteral use (Silbephylline).

Methods

Seventeen patients (nine men, eight women) took part in the study. All patients attended the out-
Brockedilator actions of xanthine derivatives administered by inhalation in asthma

Characteristics of the patients

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Sex</th>
<th>Age (y)</th>
<th>FEV₁ (l)</th>
<th>FEV₁ (% predicted)</th>
<th>sGaw (s⁻¹ kPa⁻¹)</th>
<th>Treatment*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>61</td>
<td>1.12</td>
<td>35</td>
<td>0.39</td>
<td>S, B</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>49</td>
<td>1.09</td>
<td>38</td>
<td>0.60</td>
<td>Prt, S, B</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>53</td>
<td>1.37</td>
<td>48</td>
<td>0.31</td>
<td>S, B</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>49</td>
<td>0.82</td>
<td>34</td>
<td>0.29</td>
<td>S</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>56</td>
<td>1.50</td>
<td>66</td>
<td>0.41</td>
<td>S, B</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>52</td>
<td>0.70</td>
<td>33</td>
<td>0.37</td>
<td>Prt, S, B</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>31</td>
<td>1.34</td>
<td>47</td>
<td>0.36</td>
<td>B, Theot</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>39</td>
<td>0.95</td>
<td>25</td>
<td>0.22</td>
<td>Prt, S, B</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>45</td>
<td>1.35</td>
<td>37</td>
<td>0.29</td>
<td>B</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>27</td>
<td>2.04</td>
<td>61</td>
<td>0.80</td>
<td>Prt, S, B</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>32</td>
<td>1.27</td>
<td>47</td>
<td>0.49</td>
<td>S</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>62</td>
<td>1.45</td>
<td>49</td>
<td>0.35</td>
<td>S</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>61</td>
<td>1.37</td>
<td>46</td>
<td>0.33</td>
<td>S</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>60</td>
<td>1.19</td>
<td>56</td>
<td>0.72</td>
<td>S</td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>51</td>
<td>1.28</td>
<td>39</td>
<td>0.46</td>
<td>S</td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>66</td>
<td>0.71</td>
<td>24</td>
<td>0.33</td>
<td>S</td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>31</td>
<td>0.75</td>
<td>21</td>
<td>0.19</td>
<td>Prt, S</td>
</tr>
</tbody>
</table>

Mean 1.19 41.5 0.41
SEM 0.08 3.1 0.04

*All drugs given by inhalation except for those marked †. S—salbutamol; B—beclometasone dipropionate; Prt—prednisolone; Ip—ipratropium bromide; Iso—isoprenaline; SCG—sodium cromoglycate; Fen—fenoterol; Theo—theophylline.
†Administered orally.

Patient clinics of the respiratory unit and had moderately severe asthma with a documented improvement in FEV₁ of more than 15% after 200 µg inhaled salbutamol. Patients were non-smokers; details of age, sex, pulmonary function and treatment are shown in the table. None of the subjects were taking oral β adrenoceptor agonists and all inhaled bronchodilators were omitted for eight hours before each visit. Treatment with oral and inhaled corticosteroids was continued as usual. Two patients were receiving oral theophylline preparations and these were omitted for 24 hours before the study days. All subjects gave informed consent and the study was approved by the Southampton ethical committee.

Four xanthine preparations and saline placebo were used in the study. Because of spontaneous fluctuations in the severity of asthma and intercurrent illness not all the subjects were able to receive all four preparations. Micronised theophylline and glycine theophyllinate (both from Riker Laboratories, Loughborough) were dissolved in saline to produce concentrations of 10 mg/ml (pH 5.0) and 50 mg/ml (pH 9.1) respectively. Theophylline ethylenediamine (aminophylline 250 mg/ml, Antigen Ltd, Roscrea, Ireland) was diluted with saline to a concentration of 50 mg/ml (pH 9.4) and diprophylline 125 mg/ml (pH 5.4) was prepared similarly by diluting the commercial solutionised parenteral preparation Silbephyllyne (250 mg/ml, Berk Pharmaceuticals Ltd, Eastbourne). Sodium chloride 0.9% (pH 5.2) was used as placebo control.

The solutions were administered in random order from a volume of 4 ml in a disposable Inspiron Mini-Neb nebuliser (CR Bard, Sunderland), driven by compressed air at 81 min⁻¹. Inhalation was by tidal breathing for 10 minutes, the Mini-Neb nebulisers being changed every 2.5 minutes. With this technique the amount of each drug leaving the nebuliser and inhaled by the patient was 6 mg for theophylline, 30 mg for aminophylline, 30 mg for glycine theophyllinate, and 75 mg for diprophylline.

Airway calibre was measured before and after nebulisation as airway resistance with a constant volume pressure compensated whole body plethysmography (Fenyes and Gut, Basle, Switzerland) while subjects were panting at two cycles a second for 12 seconds. The plethysmograph signals were computed by an on line microprocessor and expressed as specific airway conductance (sGaw).

All studies commenced in the morning, between 0800 and 0900 hours. On arrival in the laboratory subjects rested for 20 minutes before baseline measurements of FEV₁ (six recordings) and sGaw (five recordings) were made. Subjects then received 10 minute inhalations of saline or one of the xanthine preparations. The study was single blind and the subjects had been advised that some of the preparations would have a bitter taste but that this did not necessarily reflect an active preparation. After each inhalation measurements of sGaw were made at 1, 3, 5, 10, 15, 20, 25, and 30 minutes. On completion of the last recordings subjects inhaled 200 µg salbutamol from a metered dose inhaler and a further measurement of sGaw was made after 15 minutes.
RESULTS

The subjects had a mean (SEM) baseline FEV₁ of 1.19 (0.08) litres (42% predicted) and sGaw 0.41 (0.04) s⁻¹ kPa⁻¹. For each subject FEV₁ values varied by less than 15% between study days.

All xanthine inhalations had an unpleasant taste. This was most noticeable with the more concentrated aminophylline and diprophylline. Subjects varied in their subjective responses to the inhalations, but coughing during the first minute was frequent with all the xanthines.

All four xanthine preparations produced a significant increase in sGaw by comparison with saline placebo (fig). The response was rapid, reaching a peak within five minutes. The xanthine induced increase in sGaw was short lived, the values not being significantly different from those observed with saline placebo at 30 minutes. In the concentrations given there were no significant differences in the time course-response curves for any of the four xanthines.

Inhalation of 200 μg salbutamol from a metered dose inhaler produced an additional increase in sGaw of 135% (24%) after saline placebo, 150% (20%) after theophylline, 160% (27%) after aminophylline, 135% (23%) after diprophylline, and 150% (28%) after glycine theophyllinate. There was no significant difference in the response to salbutamol whether preceded by inhaled saline or any of the xanthine preparations.

DISCUSSION

In this group of patients with moderately severe asthma inhaled theophylline and related xanthines given as a nebulised aerosol produced a rapid but short lived bronchodilatation (fig). The degree of bronchodilatation was small compared with that produced by a conventional dose of inhaled salbutamol (200 μg) from a metered dose inhaler. All the xanthines had an unpleasant taste and produced coughing early during the inhalation, particularly the more concentrated preparations aminophylline and diprophylline.

Information on inhaled xanthine derivatives for the treatment of asthma is scant and incomplete. Two early studies using inhaled theophylline and aminophylline were encouraging, though the bronchodilatation reported was short lived. In the 1960s two uncontrolled studies reported definite benefit with inhaled aminophylline. A controlled study found aminophylline too irritant to be clinically useful, although one theophylline salt, neuphylline, did produce significant bronchodilatation. In 1976 Stewart and Block reported no useful bronchodilator effect of inhaled aminophylline, though only 62.5 mg was nebulised over five minutes and the first measurement of FEV₁ was 20 minutes after completion of nebulisation. Four subsequent studies have reported improvement in airway function with inhaled aminophylline and theophylline. The studies reported here used various drug concentrations and methods of inhalation.

The present study was designed to investigate the bronchodilator efficacy of maximally tolerated concentrations of four alkyl substituted xanthine preparations. The main limitation to dose was the solubility of the compounds and the unpleasant taste and pronounced cough produced by the concentrated preparations. We made no attempt to obtain concentration-response data. With all four xanthine derivatives inhalation produced bronchodilatation...
as reflected by an increase in sGaw, but at best the response was only 49% of that achieved with 200 μg inhaled salbutamol. The reason for the low bronchodilator efficacy of inhaled xanthines is at first sight difficult to explain since it has been proposed that these drugs and the β₂ adrenoceptor agonists cause bronchodilatation through the same final pathway, by increasing concentrations of cyclic AMP in airway smooth muscle. One explanation may be limited retention of inhaled xanthines in the airways, so that local concentrations are insufficient to produce an optimal bronchodilator effect. With oral and intravenous theophylline therapeutic efficacy is closely related to circulating drug concentrations and if serum concentrations are not maintained the airway effects are rapidly lost. In studies of inhaled methylxanthines for asthma serum theophylline concentrations have always been below 5 μg/ml and often undetectable. We did not measure serum concentrations but with the total amount of each drug inhaled concentrations of accepted therapeutic significance are most unlikely to have been achieved. The very rapid response with the inhaled route implies a local action of xanthines in the airways and the short duration of effect suggests rapid removal of the drug from its site of action.

Our results are in agreement with those of most other studies on inhaled methylxanthines in that the effect produced was very much less than that of a standard dose of inhaled β adrenoceptor agonist. Furthermore, the relatively small bronchodilator action was offset by the unpleasant taste and irritant properties of the xanthines. We conclude that the xanthine derivatives used in this study when administered by inhalation are unlikely to be of benefit in the treatment of asthma.

We are very grateful to Riker Laboratories Ltd for supplying theophylline and glycine theophyllinate and to Mrs S Foulkes for typing the manuscript.

References

Bronchodilator actions of xanthine derivatives administered by inhalation in asthma.

M J Cushley and S T Holgate

*Thorax* 1985 40: 176-179
doi: 10.1136/thx.40.3.176